Hydrogène de France Announces the World's First Plant for Mass Production of High-Powered Fuel Cells (Over 1 MW)
10.12.2019 23:00:00 EET | Business Wire | Press release
Hydrogène de France (HDF) becomes a French industrial company by launching its high-powered fuel cell production plant in Bordeaux. This plant, with an annual production capacity of 50 MW, will be the first in the world to mass produce high-powered PACs (greater than 1 MW) using PEM (Proton Exchange Membrane) technology. The industrialization and standardization of these systems reduces their cost and improves significantly their reliability and maintenance.
This plant will produce under the brand name "HDF Industry". It will integrate the Fuel Cell stacks of Canadian company Ballard, which today has the most widely deployed technology in the world. This exclusive worldwide agreement allows HDF to offer high-powered FCs whose performance and prices are adapted to the energy market.
A worldwide ambition
HDF intends to play a pioneering role in the emerging hydrogen market. Hydrogen, considered by both industrialists and governments as one of the solutions for the energy transition, is developing in multiple directions, including mobility as well as stationary applications.
HDF's vision is based on the development of hydrogen as a fuel and a vehicle for storing electricity. Renewable energies have conquered a place in the world of energy by overcoming the challenge of competitiveness. HDF believes that the time has come to take on the next challenge, that of intermittency.
An industrial reality
HDF started its industrial program 3 years ago consulting the world's leading fuel cell companies. Ballard was selected as being the ideal partner, as they have demonstrated their experience, industrial capacity and stack lifetime. HDF's industrial plan has been developed with the ClearGen and CEOG projects and with the expertise of its employees.
The HDF Industry plant will have a production capacity of 50MW of Fuel Cell per year within 5 years.
Benefiting from Ballard's know-how and HDF's unique experience in industrial hydrogen projects, this French multimegawatt fuel cell plant has a sizeable lead in the market.
Damien Havard, President and Founder of HDF:
We are particularly pleased with this cooperation with Ballard. HDF industrializes reliable FCs at a price adapted to the market. The standardization of this strategic brick will allow the production of non-polluting and competitive electricity on a large scale. HDF provides the industrial solution that was missing to develop the massive storage of renewable energy. Our market is huge: this is the end of the intermittency of renewable energies!
About Hydrogène de France: industrialist and developer of Renewstable® power plants
A specialist in hydrogen technologies, HDF develops, finances, builds and operates multimegawatt industrial power generation infrastructures.
A pioneer in its sector of activity, HDF achieved a world first in 2019 in Martinique, the ClearGen project: the installation and commissioning of a high-powered fuel cell (1 MW), using the hydrogen co-produced by the SARA refinery by transforming it into electricity. This project is funded by Europe (FCH-JU) and SARA.
HDF marketed the Renewstable® power plants, which capture intermittent renewable energy and store it massively in the form of hydrogen to produce stable, 24-hour electricity that can be controlled like a thermal power plant at a competitive price. The first Renewstable® power plant is developed in French Guiana, in collaboration with the French infrastructure fund Meridiam and SARA: the CEOG power plant is the largest in the world storing massively renewable energy via hydrogen, to produce stable and non-polluting electricity day and night for 10,000 households. CEOG will start its construction site in early 2020 and produce its first electrons in early 2022.
As an international player, HDF Energy currently has around ten Renewstable® projects in the advanced development phase in several countries.
- HDF Energy website: www.hdf-energy.com
- HDF Industry website: www.hdf-industry.com
- CEOG Power Plant Website: www.ceog.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005394/en/
Contact information
Investor and press relations:
- HDF: communication@hdf-energy.com / +33 (0)5 56 77 77 11 11
Agence 914
Salomé EON :
salome@agence914.fr
+33 6 78 86 66 48
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 10:00:00 EEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 10:00:00 EEST | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early and BCG-non-responsive patients alike, it opens up the potential for ZH9 to be a transformative bladder saving treatment.” "There is a clear and urgent need to move beyond BCG. The current treatment burden—requiring up to 18 catheterisations in the first year— detrimentally impacts real-world compliance and patient outcomes," said Ibs Mahmood, CEO of Prokarium. "Pat
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 10:00:00 EEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 10:00:00 EEST | Press release
LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Through defined use cases, LogicMonitor complements Deutsche Telekom’s existing service management, monitoring, and security tooling, helping teams anticipate, detect, and resolve issues before they impact business operations. In the United Kingdom, the partnership has delivere
VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 09:00:00 EEST | Press release
VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed on to support key CMS national coverage and CE Mark milestones. "Harry has led a medical company through this arc before. He took Endotronix from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom